Advertisement

Topics

Bronchiectasis Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

13:00 EDT 29 Jul 2017 | BioPortfolio Reports

DelveInsight's, Bronchiectasis Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Bronchiectasis. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Bronchiectasis. This report provides information on the therapeutic development for Bronchiectasis, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Alitair Pharmaceuticals Inc; Bayer AG; Chiesi Farmaceutici SpA; GlaxoSmithKline Plc; Grifols SA; Insmed Inc; Kamada Ltd; Polyphor Ltd; Recipharm AB; Vertex Pharmaceuticals Inc; Novartis Pharmaceuticals; Regend Therapeutics; Zambon SpA; Chiesi Farmaceutici S.p.A.; Vertex Pharmaceuticals Incorporated
Bronchiectasis Pipeline Drugs
Bronchiectasis Pipeline Assessment
Bronchiectasis Pipeline Analysis
Bronchiectasis Drugs under Development
Bronchiectasis Discovery drugs
Bronchiectasis Preclinical drugs
Bronchiectasis Phase I drugs
Bronchiectasis Phase II drugs
Bronchiectasis Phase III Pipeline Drugs Assessment
Bronchiectasis Preregistration drugs
Bronchiectasis Molecules in pipeline

Original Article: Bronchiectasis Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Bronchiectasis Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...